Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients

被引：33

作者：

Ferra, Christelle ^{[1
]}

Sanz, Jaime ^{[2
]}

Diaz-Perez, Miguel-Angel ^{[3
]}

Morgades, Mireia ^{[1
]}

Gayoso, Jorge ^{[4
]}

Cabrera, Jose-Rafael ^{[5
]}

Villaescusa, Teresa ^{[6
]}

Sampol, Maria-Antonia ^{[7
]}

Fernandez-Aviles, Francesc ^{[8
]}

Solano, Carlos ^{[9
]}

Ortin, Miguel ^{[10
]}

Duarte, Rafael ^{[11
]}

Cuesta, Marian ^{[12
]}

Heras, Inmaculada ^{[13
]}

de la Serna, Javier ^{[14
]}

Moraleda, Jose-Maria ^{[15
]}

Barrenetxea, Cristina ^{[16
]}

Gonzalez-Vicent, Marta ^{[3
]}

Sanz, Guillermo ^{[2
]}

Ribera, Josep-Maria ^{[1
]}

机构：

[1] Hosp Badalona Germans Trias & Pujol, Dept Hematol, Inst Catala Oncol, Josep Carreras Res Inst, Badalona, Spain

[2] Hosp La Fe, Dept Hematol, E-46009 Valencia, Spain

[3] Hosp Nino Jesus, Dept Hematol, Madrid, Spain

[4] Hosp Gen Gregorio Maranon, Dept Hematol, Madrid, Spain

[5] Hosp Puerta Hierro, Dept Hematol, Madrid, Spain

[6] Hosp Univ Salamanca, Dept Hematol, Salamanca, Spain

[7] Hosp Son Espases, Dept Hematol, Palma de Mallorca, Spain

[8] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[9] Hosp Clin Univ, Dept Hematol, Valencia, Spain

[10] Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain

[11] Hosp Duran & Reynals, Dept Hematol, Inst Catala Oncol, Lhospitalet De Llobregat, Spain

[12] Hosp Carlos Haya, Dept Hematol, Malaga, Spain

[13] Hosp Morales Meseguer, Dept Hematol, Murcia, Spain

[14] Hosp 12 Octubre, Dept Hematol, Madrid, Spain

[15] Hosp Virgen Arreixaca, Dept Hematol, Murcia, Spain

[16] Hosp Valle De Hebron, Dept Hematol, Barcelona, Spain

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 03期

关键词：

Graft failure; hematopoietic stem cell transplant; outcome; infectious complications; CORD BLOOD TRANSPLANTATION; PERIPHERAL-BLOOD; BONE-MARROW; ENGRAFTMENT; FLUDARABINE; REJECTION; RELAPSE; GVHD;

D O I：

10.3109/10428194.2014.930849

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 x 10(9)/L not reached by day + 28 after SCT from peripheral blood (PB) or bone marrow (BM) progenitors and by day + 42 after SCT from unrelated cord blood (UCB) progenitors. Secondary GF was defined as a recurrent ANC < 0.5 x 10(9)/L. Eighty-nine patients with GF were reported, and 80 patients received a second SCT. The 5-year survival probability was 31% (95% confidence interval [CI]: 18-44%), and the incidences of non-relapse mortality and relapse estimated by competing risks were 47% (95% CI: 36-58%) and 21% (95% CI: 4-28%). The strategy adopted to treat GF was heterogeneous, and no approach could be unequivocally recommended for this situation. The prognosis of patients with GF was poor even after successful recovery from GF.

引用

页码：656 / 662

页数：7

共 50 条

[21] Correlation of graft immune composition with outcomes after allogeneic stem cell transplantation: Moving towards a perfect transplant
Gu, Guang
Yang, Jian-Zhu
Sun, Li-Xia
CELLULAR IMMUNOLOGY, 2018, 323 : 1 - 8
[22] Second Allogeneic Hematopoietic Cell Transplantation Following Graft Failure in Children
Yi, Eun Sang
Ju, Hee Young
Lee, Ji Won
Sung, Ki Woong
Hur, Jin
Yoo, Keon Hee
JOURNAL OF KOREAN MEDICAL SCIENCE, 2025, 40 (10)
[23] Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation
Harada, Kaito
Fuji, Shigeo
Seo, Sachiko
Kanda, Junya
Ueki, Toshimitsu
Kimura, Fumihiko
Kato, Koji
Uchida, Naoyuki
Ikegame, Kazuhiro
Onizuka, Makoto
Matsuoka, Ken-ichi
Doki, Noriko
Kawakita, Toshiro
Onishi, Yasushi
Yano, Shingo
Fukuda, Takahiro
Takanashi, Minoko
Kanda, Yoshinobu
Atsuta, Yoshiko
Ogata, Masao
BONE MARROW TRANSPLANTATION, 2020, 55 (09) : 1784 - 1795
[24] T cell replete-haploidentical second hematopoietic stem cell transplantation for primary graft failure in pediatric patients with hematologic malignancies
Mochizuki, Kazuhiro
Sano, Hideki
Akaihata, Mitsuko
Kobayashi, Shogo
Waragai, Tomoko
Ohara, Yoshihiro
Takahashi, Nobuhisa
Ito, Masaki
Ikeda, Kazuhiko
Ohto, Hitoshi
Kikuta, Atsushi
PEDIATRIC TRANSPLANTATION, 2017, 21 (07)
[25] Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation
Merli, Pietro
Caruana, Ignazio
De Vito, Rita
Strocchio, Luisa
Weber, Gerrit
Del Bufalo, Francesca
Buatois, Vanessa
Montanari, Paolo
Cefalo, Maria Giuseppina
Pitisci, Angela
Algeri, Mattia
Galaverna, Federica
Quintarelli, Concetta
Cirillo, Valentina
Pagliara, Daria
Ferlin, Walter
Ballabio, Maria
De Min, Cristina
Locatelli, Franco
HAEMATOLOGICA, 2019, 104 (11) : 2314 - 2323
[26] Allogeneic peripheral blood stem cell (PBSC) transplantation in two patients with graft failure
Stachel, D
Schmid, I
Straka, C
Handgretinger, R
Kolb, HJ
Haas, RJ
BONE MARROW TRANSPLANTATION, 1995, 16 (06) : 839 - 842
[27] Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation
SN Wolff
Bone Marrow Transplantation, 2002, 29 : 545 - 552
[28] Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation
Locatelli, Franco
Lucarelli, Barbarella
Merli, Pietro
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (01) : 23 - 36
[29] Incidence of ocular manifestations in patients with graft versus host disease after allogeneic stem cell transplant in Riyadh, Saudi Arabia
Aldebasi, Tariq
Bashir, Rabia
Gangadharan, Shiji
Shaheen, Naila A.
Alhussain, Basil
Almudhaiyan, Tariq
Alahmari, Bader
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2022, 15 (07) : 1149 - 1156
[30] Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation
Chen, Sophia
Zeiser, Robert
FRONTIERS IN IMMUNOLOGY, 2020, 11

← 1 2 3 4 5 →